A Phase 1, Open-label Study Evaluating the Safety and Tolerability of Escalating Doses of DLYE5953A in Patients with Refractory Solid Tumors

Trial Profile

A Phase 1, Open-label Study Evaluating the Safety and Tolerability of Escalating Doses of DLYE5953A in Patients with Refractory Solid Tumors

Completed
Phase of Trial: Phase I

Latest Information Update: 08 Dec 2017

At a glance

  • Drugs DLYE 5953A (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions
  • Sponsors Genentech
  • Most Recent Events

    • 04 Dec 2017 Status changed from active, no longer recruiting to completed.
    • 11 Oct 2016 Results (n=57, as of 31st December 2015) presented at the 41st European Society for Medical Oncology Congress
    • 01 Jun 2016 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top